Frazier Life Sciences Public Fund, L.P. - Jun 30, 2025 SCHEDULE 13G/A Report for Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share (LXEO)

Filing Manager
Frazier Life Sciences Public Fund, L.P.
Reporting Manager
Frazier Life Sciences Public Fund, L.P.
Security
Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share
Symbol
LXEO
Shares outstanding
53.9M shares
Disclosed Ownership
3.07M shares
Ownership
5.7%
Form type
SCHEDULE 13G/A
Date filed
8/14/2025, 01:40 PM
Date of event
Jun 30, 2025
Previous filing
Jun 4, 2025
SEC
View on sec.gov

Reporting Managers (20)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Frazier Life Sciences Public Fund, L.P. 5.7% 3.07M 0 3.07M /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
FHMLSP, L.P. 5.7% 3.07M 0 3.07M /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
FHMLSP, L.L.C. 5.7% 3.07M 0 3.07M /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Frazier Life Sciences Public Overage Fund, L.P. 1.2% 625K 0 625K /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.
FHMLSP Overage, L.P. 1.2% 625K 0 625K /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.
FHMLSP Overage, L.L.C. 1.2% 625K 0 625K /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.
Frazier Life Sciences X, L.P. 0.2% 87.4K 0 87.4K /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
FHMLS X, L.P. 0.2% 87.4K 0 87.4K /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
FHMLS X, L.L.C. 0.2% 87.4K 0 87.4K /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. 0.4% 233K 0 233K /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
FHMLS XI, L.P. 0.4% 233K 0 233K /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
FHMLS XI, L.L.C. 0.4% 233K 0 233K /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P. 0.8% 406K 0 406K /s/ Gordon Empey By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
FHMLS XII, L.P. 0.8% 406K 0 406K /s/ Gordon Empey By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
FHMLS XII, L.L.C. 0.8% 406K 0 406K /s/ Gordon Empey By Gordon Empey, General Counsel of FHMLS XII, L.L.C.
James N. Topper 0.2% 87.4K 0 87.4K /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Patrick J. Heron 0.2% 87.4K 0 87.4K /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Albert Cha 0% 0 0 0 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
James Brush 0% 0 0 0 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Daniel Estes 0% 0 0 0 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022